[go: up one dir, main page]

BRPI0816116A2 - Derivados de indol 2,3-substituídos para o tratamento de infecções virais. - Google Patents

Derivados de indol 2,3-substituídos para o tratamento de infecções virais.

Info

Publication number
BRPI0816116A2
BRPI0816116A2 BRPI0816116-0A2A BRPI0816116A BRPI0816116A2 BR PI0816116 A2 BRPI0816116 A2 BR PI0816116A2 BR PI0816116 A BRPI0816116 A BR PI0816116A BR PI0816116 A2 BRPI0816116 A2 BR PI0816116A2
Authority
BR
Brazil
Prior art keywords
treatment
viral infections
substituted indol
indol derivatives
derivatives
Prior art date
Application number
BRPI0816116-0A2A
Other languages
English (en)
Inventor
Gopinadhan N Anilkumar
Frank Bennett
Tin-Yau Chan
Kevin X Chen
Mousumi Sannigrahi
Francisco Velazquez
Srikanth Venkatraman
Qingbei Zeng
Jose S Duca
Charles A Lesburg
Joseph A Kozlowski
F George Njoroge
Stuart B Rosenblum
Neng-Yang Shih
Stephen J Gavalas
Yueheng Jiang
Patrick A Pinto
Haiyan Pu
Oleg B Selyutin
Bancha Vibulbhan
Li Wang
Wanli Wu
Weiying Yang
Yuhua Huang
Hsueh-Cheng Huang
Robert Palermo
Boris Feld
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of BRPI0816116A2 publication Critical patent/BRPI0816116A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
BRPI0816116-0A2A 2007-08-29 2008-08-27 Derivados de indol 2,3-substituídos para o tratamento de infecções virais. BRPI0816116A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96874507P 2007-08-29 2007-08-29
PCT/US2008/010130 WO2009032116A1 (en) 2007-08-29 2008-08-27 2, 3-substituted indole derivatives for treating viral infections

Publications (1)

Publication Number Publication Date
BRPI0816116A2 true BRPI0816116A2 (pt) 2015-03-03

Family

ID=40220015

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0816116-0A2A BRPI0816116A2 (pt) 2007-08-29 2008-08-27 Derivados de indol 2,3-substituídos para o tratamento de infecções virais.

Country Status (18)

Country Link
US (1) US8143305B2 (pt)
EP (1) EP2197842B1 (pt)
JP (1) JP5272007B2 (pt)
KR (1) KR20100049667A (pt)
CN (1) CN101842353A (pt)
AR (1) AR068107A1 (pt)
AU (1) AU2008295476B2 (pt)
BR (1) BRPI0816116A2 (pt)
CA (1) CA2697375A1 (pt)
CL (1) CL2008002538A1 (pt)
CO (1) CO6321236A2 (pt)
EC (1) ECSP10010002A (pt)
MX (1) MX2010002319A (pt)
PE (1) PE20090995A1 (pt)
RU (1) RU2010111550A (pt)
TW (1) TW200924751A (pt)
WO (1) WO2009032116A1 (pt)
ZA (1) ZA201001335B (pt)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110104109A1 (en) * 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
JP5211068B2 (ja) 2006-12-22 2013-06-12 メルク・シャープ・アンド・ドーム・コーポレーション Hcvおよび関連するウイルス疾患の治療または予防のための4,5−環インドール誘導体
KR20090094154A (ko) 2006-12-22 2009-09-03 쉐링 코포레이션 Hcv 및 관련 바이러스 감염을 치료 또는 예방하기 위한 4,5-환 환상 인돌 유도체
EP2081922B1 (en) 2006-12-22 2012-02-01 Schering Corporation 5,6-Ring annulated indole derivatives and use thereof
TW200911807A (en) * 2007-08-29 2009-03-16 Schering Corp 2,3-substituted azaindole derivatives and methods of use thereof
BRPI0815811A2 (pt) * 2007-08-29 2015-02-18 Schering Corp Derivados de indol substituído e métodos de uso dos mesmos
JP5416708B2 (ja) * 2007-11-16 2014-02-12 メルク・シャープ・アンド・ドーム・コーポレーション 3−アミノスルホニル置換インドール誘導体およびそれらの使用方法
MX2010005356A (es) * 2007-11-16 2010-05-27 Schering Corp Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos.
EP2303893B1 (en) * 2008-06-13 2016-12-07 Merck Sharp & Dohme Corp. Tricyclic indole derivatives
ATE555096T1 (de) 2008-07-23 2012-05-15 Hoffmann La Roche Heterocyclische verbindungen als viruzide
BRPI0920513A2 (pt) 2008-09-26 2019-09-24 F Hoffamann La Roche Ag derivados de pirina ou pirazina para tratar hcv
MX2011011112A (es) 2009-04-25 2011-11-18 Hoffmann La Roche Compuestos antivirales heterociclicos.
AU2010253791A1 (en) 2009-05-29 2011-11-24 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C
AR077004A1 (es) 2009-06-09 2011-07-27 Hoffmann La Roche Compuestos heterociclicos antivirales
AU2010264802A1 (en) 2009-06-24 2012-01-19 F. Hoffmann-La Roche Ag Heterocyclic antiviral compound
CN102498100A (zh) 2009-09-21 2012-06-13 弗·哈夫曼-拉罗切有限公司 抗病毒杂环化合物
US20120232062A1 (en) * 2009-10-20 2012-09-13 Eiger Biopharmaceuticals, Inc. Azaindazoles to treat flaviviridae virus infection
CA2782024A1 (en) 2009-11-25 2011-06-03 Schering Corporation Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
US20130156731A1 (en) 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
WO2011112429A1 (en) 2010-03-09 2011-09-15 Schering Corporation Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
EP2598149A4 (en) 2010-07-26 2014-09-10 Merck Sharp & Dohme SUBSTITUTED BIPHENYLENE COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF VIRUS DISEASES
AU2011314168A1 (en) 2010-09-29 2013-04-04 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
MX2013006467A (es) 2010-12-09 2013-10-01 Amgen Inc Compuestos biciclicos como inhibidores pim.
EP2688886A1 (en) 2011-03-22 2014-01-29 Amgen Inc. Azole compounds as pim inhibitors
KR20130138840A (ko) 2011-04-13 2013-12-19 머크 샤프 앤드 돔 코포레이션 2''-치환된 뉴클레오시드 유도체 및 바이러스성 질환의 치료를 위한 그의 사용 방법
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
EP2755981A4 (en) 2011-09-14 2015-03-25 Merck Sharp & Dohme SILICULAR HETEROCYCLIC DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
CA2865962A1 (en) 2012-02-29 2013-09-06 Institute For Hepatitis And Virus Research Inhibitors of hepatitis b virus covalently closed circular dna formation and their method of use
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
AR092959A1 (es) 2012-10-17 2015-05-06 Merck Sharp & Dohme Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
WO2014059902A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. 2'-disubstituted substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
WO2014059901A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. 2'-cyano substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
US9732111B2 (en) 2012-11-19 2017-08-15 Merck Sharp & Dohme Corp. 2′-alkynyl substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
EP3010512B1 (en) 2013-06-18 2017-12-27 Merck Sharp & Dohme Corp. Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2014205593A1 (en) 2013-06-24 2014-12-31 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for treatment of viral diseases
WO2014205592A1 (en) 2013-06-24 2014-12-31 Merck Sharp & Dohme Corp. Heterocyclic compounds and methods of use thereof for treatment of hepatitis c
US10167298B2 (en) 2013-10-30 2019-01-01 Merck Sharp & Dohme Corp. Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof
CN105254617A (zh) * 2014-07-16 2016-01-20 南开大学 抗丙型肝炎病毒(hcv)吲哚类化合物及其制备方法和用途
TW202140422A (zh) * 2014-10-06 2021-11-01 美商維泰克斯製藥公司 囊腫纖維化症跨膜傳導調節蛋白之調節劑
MX2017016875A (es) 2015-06-26 2018-04-24 Takeda Pharmaceuticals Co Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores de receptor muscarinico colinergico m1.
US10548899B2 (en) 2015-10-20 2020-02-04 Takeda Pharmaceutical Company Limited Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity
ES2946970T3 (es) 2016-03-31 2023-07-28 Vertex Pharma Regulador de conductancia transmembrana de moduladores de fibrosis quística
US10899788B2 (en) 2016-06-20 2021-01-26 Merck Sharp & Dohme Corp. Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases
BR112019006213A2 (pt) 2016-09-30 2019-06-18 Vertex Pharma modulador de regulador de condutância transmembranar de fibrose cística, composições farmacêuticas, métodos de tratamento e processo para fazer o modulador
WO2018086531A1 (zh) * 2016-11-08 2018-05-17 正大天晴药业集团股份有限公司 作为cccDNA抑制剂的磺酰胺类化合物
LT3551622T (lt) 2016-12-09 2021-02-25 Vertex Pharmaceuticals Incorporated Cistinės fibrozės transmembraninio laidumo reguliatoriaus moduliatorius, farmacinė kompozicija, gydymo būdai, ir moduliatoriaus gamybos būdas
MA54105A (fr) 2017-06-08 2021-09-15 Vertex Pharma Méthodes de traitement de la fibrose kystique
WO2019018395A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated METHODS OF TREATING CYSTIC FIBROSIS
CA3071278A1 (en) 2017-08-02 2019-02-07 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
US10988454B2 (en) * 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
TWI719349B (zh) 2017-10-19 2021-02-21 美商維泰克斯製藥公司 Cftr調節劑之結晶形式及組合物
WO2019113476A2 (en) 2017-12-08 2019-06-13 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
TWI748194B (zh) 2018-06-28 2021-12-01 德商菲尼克斯 Fxr有限責任公司 含有雙環核心部分之新穎lxr調節劑
CN116874406A (zh) * 2023-06-25 2023-10-13 山东大学 一种吲哚酰基磺酰胺类化合物及其制备方法与应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE648639C (de) 1935-05-19 1937-08-05 I G Farbenindustrie Akt Ges Verfahren zur Darstellung von Dipyrrolen
US3632805A (en) 1967-12-08 1972-01-04 Sumitomo Chemical Co Process for producing 1-aminoalkyl-benzodiazepine derivatives
AU575854B2 (en) 1983-10-04 1988-08-11 Shionogi & Co., Ltd. 7beta-(carboxyalkenamido) cephalosporins
US5017380A (en) 1986-07-02 1991-05-21 Shionogi & Co., Ltd. Gelatin hard capsule containing crystalline hydrate of oral cephalosporin
NZ220764A (en) 1986-07-02 1989-09-27 Shionogi & Co Crystalline form of 7beta((z)-2-(2-aminothiazol-4-yl)-4- carboxybut-2-enoylamino)-3-cephem-4-carboxylic acid and pharmaceutical compositions
CA2038925A1 (en) 1990-03-26 1991-09-27 Takashi Sohda Indole derivatives, their production and use
JPH04149429A (ja) 1990-10-12 1992-05-22 Fuji Photo Film Co Ltd ハロゲン化銀カラー反転写真感光材料およびそれを用いた画像形成方法
IT1278077B1 (it) 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
NZ335276A (en) 1996-10-18 2000-09-29 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
AU757072B2 (en) 1997-08-11 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptide analogues
FR2768146B1 (fr) 1997-09-05 2000-05-05 Oreal Nouveaux composes de la famille des indole-carboxyliques et leur utilisation
SK14192002A3 (sk) 2000-04-05 2003-03-04 Schering Corporation Makrocyklické zlúčeniny, farmaceutický prostriedok s ich obsahom a ich použitie
PL358591A1 (en) 2000-04-19 2004-08-09 Schering Corporation Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising alkyl and aryl alanine p2 moieties
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
HUP0303358A3 (en) 2000-07-21 2005-10-28 Schering Corp Novel peptides as ns3-serine protease inhibitors of hepatitis c virus and pharmaceutical compositions containing them
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
NZ523782A (en) 2000-07-21 2005-10-28 Dendreon Corp Peptides as NS3-serine protease inhibitors of hepatitis C virus
KR20030036917A (ko) 2000-10-10 2003-05-09 스미스클라인 비참 코포레이션 치환된 인돌, 이를 함유하는 약제학적 조성물, 및 이의PPAR-γ결합제로서의 용도
JP4368581B2 (ja) 2000-12-12 2009-11-18 シェーリング コーポレイション C型肝炎ウイルスのns3−セリンプロテアーゼ阻害剤としてのジアリールペプチド
JP2004518658A (ja) 2000-12-18 2004-06-24 イーライ・リリー・アンド・カンパニー 新規なsPLA2インヒビター
DE60223544T2 (de) 2001-02-22 2008-09-25 University Of Bradford, Bradford Pyrrolo-indol- und pyrrolo-chinolin-derivate als prodrugs zur tumorbehandlung
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
WO2004035571A1 (en) 2002-10-15 2004-04-29 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
US20050075331A1 (en) 2003-10-06 2005-04-07 Pratt John K. Anti-infective agents
RU2360913C2 (ru) 2003-05-30 2009-07-10 Жемэн Икс Фармасьютикалз Канада Инк. Тригетероциклические соединения, фармацевтические композиции на их основе и способы лечения рака
GB0323845D0 (en) 2003-10-10 2003-11-12 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
AR046833A1 (es) 2003-11-10 2005-12-28 Schering Corp Anticuerpos anti-interleuquina-10
US8067379B2 (en) 2004-02-27 2011-11-29 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
AU2005218553A1 (en) 2004-03-01 2005-09-15 Viropharma Incorporated Pyranoindole derivatives and the use thereof for the treatment of Hepatitis C virus infection or disease
US20050249702A1 (en) 2004-05-06 2005-11-10 Schering Corporation (1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis C virus NS3/NS4a serine protease
EP1604988A1 (en) 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
WO2007084413A2 (en) 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
CA2577413A1 (en) 2004-09-23 2006-03-30 Wyeth Carbazole and cyclopentaindole derivatives to treat infection with hepatitis c virus
DE102004047272A1 (de) 2004-09-24 2006-04-06 Schering Ag Inhibitoren der löslichen Adenylatzyklase
WO2006046030A2 (en) 2004-10-26 2006-05-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents
JP4149429B2 (ja) 2004-10-26 2008-09-10 本田技研工業株式会社 車両の走行安全装置
EP1844042A1 (en) * 2005-01-14 2007-10-17 Genelabs Technologies, Inc. Indole derivatives for treating viral infections
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
MX2008004024A (es) 2005-09-23 2009-02-27 Schering Corp Antagonistas de receptor de glutamato metabotropico-1 tetraciclicos fusionados como agentes terapeuticos.
JP2009523732A (ja) * 2006-01-13 2009-06-25 ピーティーシー セラピューティクス,インコーポレーテッド C型肝炎の治療方法
JP2009526070A (ja) 2006-02-09 2009-07-16 シェーリング コーポレイション Hcvプロテアーゼ阻害薬とhcvポリメラーゼ阻害薬との組み合わせ、ならびにそれらに関連する処置の方法
KR20090094154A (ko) * 2006-12-22 2009-09-03 쉐링 코포레이션 Hcv 및 관련 바이러스 감염을 치료 또는 예방하기 위한 4,5-환 환상 인돌 유도체

Also Published As

Publication number Publication date
ZA201001335B (en) 2010-12-29
CA2697375A1 (en) 2009-03-12
AR068107A1 (es) 2009-11-04
AU2008295476A1 (en) 2009-03-12
KR20100049667A (ko) 2010-05-12
US20110033417A1 (en) 2011-02-10
PE20090995A1 (es) 2009-08-03
ECSP10010002A (es) 2010-03-31
TW200924751A (en) 2009-06-16
JP5272007B2 (ja) 2013-08-28
CO6321236A2 (es) 2011-09-20
AU2008295476B2 (en) 2013-08-01
CL2008002538A1 (es) 2009-07-17
EP2197842A1 (en) 2010-06-23
MX2010002319A (es) 2010-03-22
WO2009032116A1 (en) 2009-03-12
CN101842353A (zh) 2010-09-22
JP2010537979A (ja) 2010-12-09
RU2010111550A (ru) 2011-10-10
US8143305B2 (en) 2012-03-27
EP2197842B1 (en) 2012-05-23

Similar Documents

Publication Publication Date Title
BRPI0816116A2 (pt) Derivados de indol 2,3-substituídos para o tratamento de infecções virais.
ATE541845T1 (de) 2,3-substituierte azaindolderivate zur behandlung von virusinfektionen
LTC2137143I2 (lt) Pleuromutilino dariniai, skirti mikrobų sukeltų ligų gydymui
IL184242A0 (en) Indole derivatives for treating viral infections
BRPI0811718A2 (pt) Derivados de 3,3-espiroindolinona
SMP200900085B (it) 3-imidazolil-indoli per il trattamento di malattieproliferative.
DK2109602T3 (da) Tetracyclinderivater til behandling af bakterielle, virale og parasitiske infektioner
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
EP4125244C0 (en) HASH BASED MULTIHOSTING
DK2300443T3 (da) Triazolderivater, der er anvendelige til behandling af sygdomme
BRPI0814958A2 (pt) Compostos de indazol ou indol, composição, e, método para preparar uma composição.
EA201000888A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и 2-фенилциклогексан-1,3,5-трионы в качестве гербицидов
DE602008005634D1 (de) 1,1,1-trifluor-2-hydroxy-3-phenylpropan-derivate
DK2041093T3 (da) Til behandling af GPR38-receptor medierede sygdomme anvendelige piperazinylderivativer
BRPI0911577A8 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
WO2009071689A3 (de) 5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
DE602006020482D1 (de) 1,5-substituierte indol-2-yl amidderivative
EA201000258A1 (ru) Новые гербициды
BRPI0916363A2 (pt) derivados de 4,5-di-hidro-oxazol-2-ila
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.
PT2056805E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de reacção tecidular
CL2007001542A1 (es) Compuestos derivados de aminotiazoles, composicion farmaceutica; y uso para el tratamiento de infecciones bacterianas.
BRPI0816679A2 (pt) Derivados de ftalazinona.
MA28576B1 (fr) Procede de preparation de derives n-piperidino-1,5-diphenylpyrazole-3-carboxamide.
DK1881830T3 (da) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinolin-derivater til behandling af infertilitet

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.